Form 4: Kodiak Sciences CFO Sells Shares Under 10b5-1 Plan

Kodiak Sciences Inc. CFO John A. Borgeson reported transactions involving the sale of common stock and the acquisition of stock options under a pre-arranged 10b5-1 trading plan.

Summary

• John A. Borgeson, Chief Financial Officer of Kodiak Sciences Inc., executed a series of transactions on April 2, 2026.
• These transactions included the acquisition of 30,000 stock options at a price of $1.04 per share.
• Concurrently, Borgeson sold a total of 29,399 shares of common stock through multiple transactions at weighted-average prices ranging from $38.68 to $41.91.
• These sales were conducted under a Rule 10b5-1 trading plan adopted on September 29, 2025, which is designed to comply with affirmative defense conditions for insider trading.
• Following these transactions, Borgeson beneficially owns 200,624 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the CFO is selling shares, the execution under a 10b5-1 plan mitigates concerns about insider knowledge, and the acquisition of options suggests some level of confidence in future performance.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating adherence to pre-determined trading strategies and regulatory compliance.
• The acquisition of 30,000 stock options at a favorable price of $1.04 suggests potential future upside for the executive.
• The executive continues to hold a significant number of shares (200,624) after the reported sales.

Negatives

• The sale of a substantial number of shares (29,399) by the CFO could be interpreted negatively by the market, potentially signaling a lack of confidence in near-term stock performance, despite being executed under a 10b5-1 plan.
• The weighted-average sale prices indicate a range of market values at which the shares were disposed of.

Risks

• The primary risk is the market's perception of the CFO's stock sales, which could lead to negative investor sentiment and downward pressure on the stock price, irrespective of the 10b5-1 plan's compliance.
• The effectiveness and continued validity of the 10b5-1 plan itself could be subject to regulatory scrutiny or interpretation.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the acquisition of stock options by the CFO suggests a potential belief in future stock appreciation, while the sales under the 10b5-1 plan reflect a pre-determined strategy for managing equity holdings.

Management Comments

• The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 29, 2025.
• The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing insider transactions are common in the biotechnology and pharmaceutical sectors, where stock-based compensation and executive portfolio management are prevalent. The use of 10b5-1 plans is a standard practice for executives to diversify holdings or raise capital while mitigating insider trading concerns.

Stakeholder Impact

• Shareholders: May interpret the CFO's sales as a negative signal, potentially impacting stock price, despite the 10b5-1 plan.
• Employees: May also view insider sales with concern, potentially affecting morale.
• Management: Demonstrates adherence to compliance protocols through the use of a 10b5-1 plan.

Next Steps

• The Reporting Person may continue to execute transactions under the existing 10b5-1 plan.
• The company may receive requests for detailed transaction information from the SEC or security holders.

Key Dates

Recommendation

The filing indicates a routine transaction under a pre-established 10b5-1 plan by a key executive. While insider selling can be a negative indicator, the structured nature of the sale under a compliance plan suggests it's not necessarily a reflection of immediate negative news. The acquisition of options also provides a counterbalancing positive signal. Therefore, a 'hold' recommendation is appropriate pending further company performance data.

Keywords

Kodiak Sciences Inc., KOD, Form 4, Insider Trading, 10b5-1 Plan, Stock Options, Share Sales, Beneficial Ownership, John A. Borgeson, Chief Financial Officer